Harrow Health, Inc. Announces Board and Committee Changes
March 17, 2020 at 05:00 pm IST
Share
Harrow Health, Inc. announced the appointment of Teresa Sparks to its Board of Directors. As of March 15, 2020, Stephen G. Austin, who has served as the Harrow Health Audit Committee Chairman since 2012, is resigning and Teresa Sparks will assume the role of Audit Committee Chairwoman. Ms. Sparks is a healthcare senior executive with extensive public corporate leadership in addition to private equity experience, having led two initial public offerings, a leveraged buy-out, and multiple mergers and acquisitions. She is the CFO and Executive Vice President of Envision Healthcare. Before joining Envision Healthcare, she was the interim CFO at Brookdale Senior Living and the CFO at Surgery Partners and its predecessor company, Symbion. Ms. Sparks began her career with Deloitte in Nashville, Tennessee and healthcare was her primary area of focus. Her public company experience incorporates strategy development, risk assessment, investor relations, and corporate governance. She has served as the chairperson for the Nashville Health Care Council's Leadership Health Care (LHC) program and served on the Board of Trustees at Trevecca Nazarene University.
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.